FDA: Subsidiary of Monsanto? | DORway
September 21, 2010 § Leave a comment
By Betty Martini, Mission Possible International
Dear Dr. Friedman:
Is this why you looked at the case histories of those who suffered shattered lives from the agony of Aspartame Disease for years, and did absolutely NOTHING!? Or is this Monsanto’s reward for your lack of concern of this plague on the consumer public in 100 countries. You worked for the ( government sponsored!) National Cancer Institute??!! And you read the Bressler Report, the FDA audit, showing aspartame triggered brain tumors, mammary tumors, ovarian tumors, pancreatic tumors, uterine tumors, pituitary adenomas, etc., etc., and turned the other way, even sent the cases where victims died from these brain tumors. Just silence. No wonder when Dr. Olney made world news about the brain tumor/aspartame connection you got on 60 Minutes defending Monsanto. How long has this position been considered? How relevant it was for Dr. Virginia Weldon (V.P.for Public Policy at Monsanto) to have also been on that show since later she was considered for the FDA Commissioner post. Perhaps you can understand why I call the FDA, Monsanto’s Washington Branch Office.
I told you previously Monsanto who made Celebrex knows aspartame hardens the synovial fluids and triggers agonizing joint pain. This is their way to make even more money on the victims treating the problem their product caused. Now that it has been publicized that 10 people died in 13 weeks and the other problems I guess we won’t expect the FDA to recall it -especially now that you will work for the company.
Why not just change the name of the FDA to Monsanto Chemical Company and then people won’t bother to put faith in the FDA or think they might have some interest in safe Food and Drugs? You know Aspartame Disease has been declared a world epidemic, and you not only do nothing about it
but go and work for the manufacturer as V.P. of Searle who originally made it, bought by Monsanto in l985.
I have told you if Neotame, a more potent aspartame, is approved the FDA will start a war because the world now knows, thanks to Internet. So now I’m wondering is this your job to get done before you leave. I mean, isn’t this the way its done?? After all, Dr. Arthur Hull Hayes, who approved aspartame after over-ruling a Board of Inquiry went to work for Searle’s PR firm. And when two U.S. Prosecutors were asked to indict Searle for fraud on the aspartame studies they went to work for
Sidley & Austin, Searle’s lawyers defending the case and didn’t do their job. And then Dr. David Kessler, who also got case histories and knew aspartame was a killer, turns around and grants blanket approval to this drug that interacts with other drugs who even Searle in their secret trade information (on www.dorway.com) admitted couldn’t be used for everything. Then he goes to work for Yale. Who got him the job?
Now what shall we expect from you, Dr. Friedman? Let’s see, you did nothing about aspartame, and Celebrex hasn’t been recalled. I guess thats reward enough for this job. Will your influence see that Neotame is approved so people can be dropping in the streets from an even more potent aspartame? Is that what all this is about?
Tell me something, Dr. Friedman, does the FDA not care that an addictive drug that interacts with other drugs is masquerading as an additive, been given blanket approval like sugar, and fed to even infants in food and drugs? I know to ask the question is to answer it. But here’s some more information from Dr. H. J. Roberts newly released book BREAST IMPLANTS OR ASPARTAME (NUTRASWEET) DISEASE? (1 800 – 814-9800):
THE ADDICTION ISSUE
“The extraordinary consumption of aspartame soft drinks and other “diet” products by many persons with aspartame disease, and their clinical addiction to them are impressive.
The transformation of phenylalanine to dopamine and dopamine metabolites is germane to this issue. Phenylalanine becomes converted to dopamine and then to norepinephrine and epinephrine (Roberts l989). This assumes significance because dopaminergic pathways (especially from the neural
tegmentum to the nucleus accumbens and medial frontal cortex) play a role in opiate dependence (National Consensus Develop-ment Panel l998). Additionally, abnormal excitation of the locus ceruleus (the major brain site of catecholamine synthesis for adrenergic pathways) underlies some of the physical features of opiate withdrawal.
Addictive drugs flood synapses with dopamine, which carries a “pleasure message” from one nerve cell to another in the “reward pathway”…thereby creating a “high.” For instance, cocaine blocks the
reuptake of dopamine, thereby acting as an indirect dopamine agonist. Such repeated rushes can result in desensitization of the brain to dopamine.
* During et al (l987) demonstrated that changes in brain phenylalanine may selectively affect production of the dopamine molecule, which becomes preferentially released into synapses.
* Myers and Melchior (l977) found that a dopamine-dopaldehyde condensation product (tetrahydropapaveroline) caused rats to drink increasingly large amounts of alcohol solutions that they usually reject.
* Researchers have advanced the concepts that increased dopamine influences the addiction effects of cocaine and that dopamine-receptor agonists themselves might be addictive in cocaine users IKoob
Another insight derives from the behavioral cross-sensitization to cocaine after repeated low level exposure to formaldehyde. Sorg et al (l998) believe that this phenomenon has relevance to multiple chemical sensitivity in humans who manifest fatigue, irritability, problems with memory and concentration, depression, headache, muscle/joint pain, and gastrointestinal dysfunction… perhaps reflecting limbic system sensitization.”
Look what the FDA has done to our children!
First, FDA allows a drug that is a teratogen ,triggers birth defects, a deadly neurotoxin (Dr. Louis Elsas testimony before congress, pediatric professor,genetics, Emory, www.dorway.com) not even to have a warning for pregnant women. And you have certainly received enough cases of the murder of babies in their mother’s womb, and those with birth defects. Neurosurgeon Russell Blaylock, M.D., (author of Excitotoxins: The Taste That Kills – 1 800 -643-2665) says in his book that aspartame triggers ADD and autism and even if the baby survives you can see the problems when the child reaches puberty and has to use the more complex part of its brain. Then FDA even allows it in pediatric drugs, and we have a list of them on www.dorway.com
The FDA doesn’t even care this drug depletes serotonin which triggers manic depression, rage, paranoia, panic attacks, anxiety, paranoia, suicidal tendencies,etc. And so many wonder why young children are committing so many crimes!! Consider the interaction of aspartame which is a psycho drug with psycho drugs prescribed for the affliction aspartame triggers! And just think, Dr. Friedman, children don’t even have to buy dope from a drug pusher – they can buy this addictive drug at the supermarket with FDA approval!
Well, Monsanto wanted their Vice President Dr. Virginia Weldon to head the FDA, but it didn’t happen, too much publicity What difference does it make if industry goes to FDA or FDA goes to industry? Now they have a better deal, they have the former acting Commissioner of the FDA working for them! The FDA and Monsanto can remove the revolving door. There is so much traffic they can build a bridge! What other ex-officio member will Monsanto reel in next? How many more will flip-flop across the bridge? Which reminds me, isn’t it time for Michael Taylorto reel his head again? He was at FDA when aspartame and RBGH was approved. Why he even changed the Delaney Amendment until it could be
repealed. I mean who at the FDA cares about whether you approve carcinogens. After all, your own late FDA toxicologist (who tried to stop the approval of aspartame), Dr. Adrian Gross told Congress
aspartame violated the Delaney Amendment, and “if the FDA violates its own laws who is left to protect the public?” Perhaps the Bridge should have an extension to Hugh and Spalding. Come on, Dr. Friedman, don’t keep us in suspense, let us know all the players. Why this could be made into a movie but no one would believe conflict of interest could be this blatant.
Now I understand the St. Louis Post Dispatch article in May:” Monsanto May Sell NutraSweet: Official Mum on Fate of Sweetener Unit! “I knew no one would buy the Monsanto Titanic. The article said: “There was no discussion about it,” said Tore Stole, who follows Monsanto for A. G. Edwards & Sons Inc.”No one asked any questions about it. And even though many top executives attended the all day long meeting, no one from the nutrition division was there. Analysts say Monsanto’s silence
spoke volumes about NutraSweet’s future.” Looks like Monsanto had already made their deal!
Monsanto has had several concerns. In the NutraSweet issue, stopping the recall of aspartame and getting neotame approved. Stopping the FDA from recalling Celebrex in the face of deaths. Plus we have the genetic engineering issue, and a public who doesn’t want it. Monsanto really needed even more loyalty in the FDA. Now they have FDA in their pocket with even more influence and power.
It’s the same song in the same saloon with new nudes. The corruption is exposed for all to see. Play it again, Sam!
Betty Martini, Founder Mission Possible International 770 – 242-2599
From: Charmelle2@aol.com Date: Mon, 14 Jun 1999 23:39:42 EDT To: Mission-Possible-USA@altavista.net, firstname.lastname@example.org, email@example.com, firstname.lastname@example.org Mailing-List: list email@example.com; contact firstname.lastname@example.org
Subject: Re: [aspartame] Monsanto names Former FDA Chief as VP of Searle
Monsanto Names Former FDA Chief as VP of Searle
Unit Chicago, June 14
– Monsanto Co. said former acting U.S. Food and Drug Administration commissioner Michael Friedman would join the company as the new senior vice president for clinical affairs at its G.D. Searle & Co. drug unit, which makes the hot-selling Celebrex arthritis drug.
Friedman, who oversaw the drug regulatory agency for more than a year, will begin work at Searle in July, directing planning and implementation of the company’s clinical research.
According to federal ethics guidelines, Friedman will be barred for a year from representing Searle before his former agency, including its advisory committees.
Still, Friedman established a strong reputation at the FDA, which can only help Searle, according to Ira Loss, senior vice president of Washington Analysis, an equity research firm specializing in regulatory
“It provides Searle with built-in credibility,” Loss said. “He did his job at a time when Congress was riled up, and he helped keep Congress at arm’s length.”
Both Secretary of Health and Human Services Donna Shalala and Jane Henney, the commissioner of the FDA, praised Friedman’s work during his time at the agency.
“He has distinguished himself as a leader not only within the ranks of government, but in the medical, academic, science and research communities as well,” said Shalala.
Friedman replaces the retiring John Alexander, who has held the post since 1991.
At the FDA, Friedman helped guide the agency through a congressionally mandated overhaul, which included faster drug approvals. In addition to his time as the leader of the agency, Friedman also served as the lead deputy commissioner. Friedman was also seen as a prime candidate for the
permanent commissioner position, a job that later went to Henney.
Prior to joining the FDA, Friedman worked at the government- sponsored National Cancer Institute for 12 years.
Monsanto shares fell 1 1/4 to close at 40 15/16. Jun/14/ 99 17:36 Printer Friendly Version
- Recommend on Facebook
- Tweet about it
- Subscribe to the comments on this post
- Tell a friend
- Print for later